Related Experiment Videos
[Neuroleptic malignant syndrome].
Zygmunt Chodorowski1, Jacek Sein Anand, Przemysław Rutkowski
1I Klinika Chorób Wewnetrznych i Ostrych Zatruć Akademii Medycznej w Gdańsku, 80-211 Gdańsk, ul. Debinki 7.
Przeglad Lekarski
|October 23, 2003
Summary
Neuroleptic Malignant Syndrome (NMS) is a severe adverse reaction to antipsychotic medications. Early recognition and supportive care, including bromocriptine, are crucial for managing this dangerous condition.
Area of Science:
- Pharmacology
- Toxicology
- Neurology
Context:
- Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening adverse effect associated with antipsychotic medications, particularly phenothiazines and butyrophenones.
- Patients admitted to an Intensive Toxicological Unit with pneumonia or sepsis were retrospectively identified as having received these drugs prior to NMS onset.
- The study highlights the critical need for awareness among healthcare professionals regarding NMS in psychiatric patients.
Purpose:
- To report on the clinical characteristics and management of five patients who developed Neuroleptic Malignant Syndrome (NMS) following phenothiazine or butyrophenone therapy.
- To emphasize the diagnostic challenges and treatment strategies for NMS, especially when presenting with symptoms mimicking sepsis or pneumonia.
- To underscore the importance of patient education regarding potential NMS risks during antipsychotic treatment.
Summary:
- Five patients (3 male, 2 female; age 25-62) developed NMS after receiving phenothiazine or butyrophenone antipsychotics for psychotic states.
- Clinical presentation included altered consciousness, severe muscle rigidity, hyperpyrexia (39.0-41.0°C), tachycardia, tachypnoea, and extremely elevated creatine kinase levels (23,751-112,288 U/l).
- Treatment involved drug withdrawal, intensive supportive care, respiratory support, and bromocriptine administration; one patient experienced transient thrombocytopenia. None were informed about NMS risk.
Impact:
- This case series underscores the critical importance of prompt NMS diagnosis and management in patients receiving antipsychotic medications.
- Highlights the potential for NMS to be misdiagnosed as pneumonia or sepsis, necessitating a high index of suspicion.
- Emphasizes the need for improved communication between healthcare providers and patients regarding the risks of antipsychotic drug side effects like NMS.